Lisinopril
Drug5-10 mg Lisinopril per day for seven days, depending on blood pressure.
Other names: ACE inhibitor
NCT Number: NCT01066572
This study aims to investigate the use of lisinopril to lower blood pressure in stroke patients, pre-hospital, by research-trained paramedics.
Looking for future studies?
Notify Me40 year and older
All sexes
Interventional
Phase 1
Wansbeck General Hospital, Ashington, Northumberland, United Kingdom
High blood pressure immediately following stroke is common and related to poorer stroke functional outcome and death. Although treatment of high blood pressure is well established for thre prevention of stroke, it is unclear if high blood pressure observed immediately after stroke should be lowered.
Several previous clinical trials have lowered blood pressure in acute stroke but this has not resulted in improved stroke outcome. One reason for this may be because treatment was started too late after stroke occurred. There is rapid progression of brain injury following stroke and any stroke treatment may need to be started very early to have a beneficial effect. Previous trials started blood pressure lowering after patients arrived at hospital and this was usually a significant time after stroke occurred.
The earliest time after stroke that blood pressure treatment could be started is during contact with the emergency medical services (paramedics). This research study is a pilot double blind randomised controlled trial of paramedic initiated blood pressure treatment for patients with high blood pressure immediately after stroke.
Patients with high blood pressure and suspected acute stroke will be identified and offered the opportunity to participate in the study by research trained paramedics from the North East Ambulance Service NHS Trust. Patients who agree to participate in the study will receive either lisinopril (a common blood pressure lowering medication) or 'dummy' (placebo) treatments for seven days. The first dose of medication will be given by the paramedic in the ambulance. Subsequent tablets will be given in hospital. The effects of treatment will be monitored by measuring blood pressure, neurological outcome and adverse events.
All aspects of study feasibility including recruitment rates and compliance with data collection will be recorded. The study will run for one year and recruit 60 patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
5-10 mg Lisinopril per day for seven days, depending on blood pressure.
Other names: ACE inhibitor
Matched placebo; identical tablets to Lisinopril.
Other names: Dummy drug
Time frame: 1 year
The primary outcome measure is the number of participants enrolled in the study per month.
Time frame: 1 year
The proportion of suspected acute stroke patients admitted to research sites during the trial duration who fulfilled the study eligibility criteria
Time frame: 1 year
The proportion of study eligible patients attended by a research trained paramedic
Time frame: 1 year
The proportion of study eligible patients enrolled into the study by a researc trained paramedic
Time frame: 1 year
The proportion of study eligible patients approached about the research study but not enrolled, and the reasons for non-enrolment, where possible.
Time frame: 1 year
The additional time spent on scene by research trained paramedics to enrol a participant into the study.
Time frame: 1 year
Paramedic compliance with study data collection.
Time frame: 1 year
Hospital staff compliance with study medication administration and data collection.
Time frame: 1 year
The proportion of study participants with confirmed stroke who complete seven days of study medication.
Time frame: 1 year
Clinical outcome measures are blood pressure, neurological score, dependency score and renal function.
Time frame: 1 year
Adverse events in control and intervention groups during the study.
Newcastle-upon-Tyne Hospitals NHS Trust
Other
Paramedic Initiated Lisinopril For Acute Stroke Treatment: a Pilot Randomised Controlled Trial
Acronym: PIL-FAST
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02425345
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT05589402
Bone Diseases, Brain Diseases
Harlingen, Texas, United States
View Trial DetailsNCT06750692
Brain Diseases, Cardiovascular Diseases
Afyonkarahisar, Turkey (Türkiye)
View Trial DetailsNCT04992195
Alzheimer Disease, Arterial Thromboembolism
Hong Kong
View Trial Details